The global hematology testing market is estimated to grow at a high rate during the forecast period. A number of factors such as development of technologically advanced hematology analyzers, increasing usage of flow cytometry in hematology testing, and development of high-sensitivity point-of-care hematology analyzers are fuelling the growth of the global hematology testing market. However, the slow adoption rate of hematology analyzers in emerging countries, owing to the high cost of these analyzers is one of the major factors hindering the market growth.
Emerging markets such as China, India, Brazil, and Mexico are the new revenue pockets for companies that are engaged in the development and marketing of hematology analyzers and reagents. Growing patient population, rising healthcare expenditure, and rising trends of medical tourism owing to low-cost treatments are the key factors propelling demand for hematology tests in these emerging nations.
Abbott Laboratories (U.S.), Beckman Coulter, Inc. (a subsidiary of Danaher Corporation (U.S.)), Bio-Rad Laboratories, Inc. (U.S.), Boule Diagnostics AB (Sweden), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Nihon Kohden Corporation (Japan), Roche Diagnostics (a division of F. Hoffmann-La Roche Ltd (Switzerland)), Siemens Healthcare (a division of Siemens AG (Germany)), and Sysmex Corporation (Japan) are some of the key players in the global hematology testing market. Market players primarily focus on the development of technologically advanced hematology analyzers and inorganic strategies such as strategic acquisitions and partnerships in order to ensure their growth in this market.
Scope of the Report
This report categorizes the global hematology testing market into the following segments and sub-segments:
Hematology Testing Market, By Products and Services
Hematology Testing Market, By Type of Tests
Hematology Testing Market, By End User
Hematology Testing Market, By Region